Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-Blind Study Of Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors

NCT00428597 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00428597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00428597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-Blind Study Of Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2007
Completion date
April 30, 2009
Enrollment
171 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, islet cell, carcinoma, pancreas